Tramadol was marketed as a safer alternative to traditional opioids, but clinical experience and research have demonstrated that it carries genuine risks of dependence, addiction, and a withdrawal syndrome that is uniquely complex. Unlike other opioids, tramadol acts on both mu-opioid receptors and serotonin/norepinephrine reuptake systems, producing a withdrawal that combines classic opioid withdrawal symptoms with SSRI-discontinuation-like effects including anxiety, panic attacks, and seizures. The “safe” label led to liberal prescribing practices that have contributed to tramadol becoming one of the most commonly misused prescription opioids worldwide.
How Tramadol’s Reputation Became Its Risk
“Tramadol’s danger lies precisely in its perceived safety,” says Dr. Ponlawat Pitsuwan, Physician at Phuket Island Rehab. “Patients and prescribers both believed it was fundamentally different from other opioids, which led to longer prescriptions, less monitoring, and a false sense that dependence could not develop. By the time the person realises they are dependent, they have often been taking tramadol for months or years.”
Tramadol was developed in the 1970s by Grunenthal GmbH and introduced to the market as a centrally acting analgesic with a lower abuse potential than traditional opioids. This was partly true: tramadol’s binding affinity for the mu-opioid receptor is weaker than morphine’s, and its analgesic effect depends partly on serotonin and norepinephrine reuptake inhibition rather than pure opioid action. These properties led to tramadol initially being unscheduled (not classified as a controlled substance) in many countries, including the United States until 2014.
The unscheduled status had predictable consequences: tramadol was prescribed more freely, for longer durations, and with less monitoring than Schedule II opioids like oxycodone or morphine. Patients who developed dependence were often surprised, as they had been told tramadol was “not a real opioid” or “not addictive.” In reality, tramadol’s metabolite O-desmethyltramadol (M1) has mu-opioid receptor affinity six times greater than tramadol itself, and it is this metabolite that produces the opioid effects, including dependence and euphoria, that drive misuse.
The Dual Mechanism: Why Tramadol Withdrawal Is Different
Tramadol is unique among opioids because it acts through two distinct pharmacological mechanisms simultaneously. It activates mu-opioid receptors (via its M1 metabolite) and inhibits the reuptake of serotonin and norepinephrine (via the parent compound). This dual action means tramadol withdrawal produces two overlapping syndromes.
The opioid withdrawal component resembles standard opioid withdrawal: muscle aches, nausea, diarrhoea, sweating, insomnia, and cravings. This component follows the typical opioid withdrawal timeline, beginning 12 to 24 hours after the last dose and resolving over 5 to 7 days.
The serotonergic withdrawal component is atypical for opioid withdrawal and includes severe anxiety, panic attacks, depersonalisation, confusion, paranoia, hallucinations, and, most seriously, seizures. Seizures are a recognised complication of tramadol withdrawal and can occur even in people with no seizure history. The risk is highest during abrupt discontinuation of high doses and in people who have been taking tramadol for extended periods.
| Withdrawal Component | Symptoms | Mechanism | Clinical Significance |
|---|---|---|---|
| Opioid (typical) | Muscle aches, nausea, diarrhoea, insomnia, sweating, cravings | Mu-opioid receptor vacancy | Uncomfortable but rarely dangerous with support |
| Serotonergic (atypical) | Anxiety, panic, confusion, hallucinations, depersonalisation, seizures | Serotonin and norepinephrine reuptake disruption | Seizure risk makes medical supervision essential |
This dual withdrawal syndrome makes tramadol discontinuation more complex than discontinuation of other opioids and is a strong argument for medically supervised withdrawal rather than attempting to quit at home. The seizure risk alone warrants clinical monitoring, and the psychological symptoms (paranoia, hallucinations, severe anxiety) can be profoundly distressing without appropriate pharmacological management.
The CYP2D6 Factor: Why Tramadol Hits Some People Harder
Tramadol’s conversion to its active metabolite M1 is catalysed by the liver enzyme CYP2D6. Genetic variation in CYP2D6 creates four metaboliser categories: poor metabolisers (5 to 10 percent of Caucasians, 1 to 2 percent of Asians), intermediate metabolisers, extensive (normal) metabolisers, and ultra-rapid metabolisers (1 to 10 percent of the population, with higher prevalence in Middle Eastern and North African populations).
Ultra-rapid metabolisers convert tramadol to M1 much faster and in greater quantities than normal metabolisers, experiencing stronger opioid effects, greater euphoria, and higher dependence risk from the same dose. Poor metabolisers produce little M1, experience minimal opioid effect, and are at lower risk of dependence but also receive little analgesic benefit. This genetic variability means the same dose of tramadol can produce dramatically different effects in different people, making standardised prescribing inherently imprecise.
Who Develops Tramadol Addiction
Tramadol addiction follows similar risk patterns to other opioid addictions: longer duration of use, higher doses, history of substance use disorder, co-occurring depression or anxiety, and genetic factors including CYP2D6 ultra-rapid metaboliser status. However, tramadol addiction has several distinctive features.
Because tramadol was perceived as safe, many people with tramadol addiction were initially conservative, risk-averse patients who would never have considered using a “strong” opioid. They accepted tramadol because their doctor told them it was safer, took it as prescribed, developed dependence over months, and found themselves unable to stop. The shame component is often intense because the person feels they should have been able to stop a “weak” opioid.
In many countries, particularly in Africa, the Middle East, and parts of Southeast Asia, tramadol is available over the counter or with minimal prescription controls, leading to widespread non-medical use. In West Africa, tramadol misuse has been declared a public health crisis by the WHO, with young men in particular using high doses for energy, mood enhancement, and perceived performance improvement.
Treatment for Tramadol Addiction
Treatment follows the same principles as treatment for other opioid addictions but with specific adaptations for tramadol’s dual mechanism. Medically supervised tapering is preferred over abrupt discontinuation to reduce seizure risk. The taper is typically conducted over two to four weeks, with dose reductions of 10 to 25 percent every few days, adjusted based on symptom severity.
Medication support during withdrawal may include clonidine (for opioid withdrawal symptoms), anticonvulsants such as gabapentin or pregabalin (for seizure prevention and anxiety), and short-term benzodiazepines under close monitoring if anxiety is severe. Buprenorphine (Suboxone) can be used for tramadol withdrawal management, though it addresses only the opioid component and the serotonergic withdrawal symptoms must be managed separately.
Following medical withdrawal, comprehensive rehabilitation addresses the psychological and behavioural dimensions of addiction through CBT, group therapy, and relapse prevention planning. At Phuket Island Rehab, tramadol addiction treatment is integrated into the opioid programme with specific attention to the medication’s unique pharmacology and the distinct psychological profile of patients whose addiction began with a “safe” prescription.
When Tramadol Use Has Become More Than Prescribed
If you are taking more tramadol than prescribed, if you are obtaining it from sources other than your doctor, if you experience withdrawal symptoms between doses, if you have tried to stop and could not, or if your use has escalated beyond what your pain condition requires, you have developed a dependence that may have progressed to addiction. The “safe” reputation of tramadol does not make the dependence less real or the withdrawal less difficult. Seeking medical help is the appropriate next step.
Summary
Tramadol’s marketed reputation as a safer opioid alternative has been contradicted by clinical experience. Its dual mechanism of action, combining opioid receptor activation with serotonin/norepinephrine reuptake inhibition, produces a uniquely complex dependence and withdrawal syndrome that includes seizure risk not typically associated with opioid withdrawal. Genetic variation in CYP2D6 means the same dose affects different people dramatically differently. The “safe” label led to liberal prescribing, extended durations of use, and a population of people with tramadol addiction who are often shocked to find themselves dependent on what they were told was a minor painkiller.
“I have treated hundreds of patients whose tramadol addiction began with a legitimate prescription and a reassurance from their doctor that this medication was different,” says Dr. Ponlawat Pitsuwan. “It is different, but not in the way they were told. Its dual mechanism makes the withdrawal more complex, not less. The good news is that with proper medical management, tramadol withdrawal is entirely manageable, and recovery is very much achievable.”
Frequently Asked Questions
Is tramadol really an opioid?
Yes. Tramadol is classified as an opioid analgesic. While its binding affinity for the mu-opioid receptor is weaker than that of morphine or oxycodone, its active metabolite (O-desmethyltramadol) has significant opioid activity. Tramadol produces opioid effects including pain relief, euphoria, respiratory depression (at high doses), physical dependence, and addiction. It was reclassified as a Schedule IV controlled substance in the United States in 2014, acknowledging its abuse and dependence potential.
Can tramadol withdrawal cause seizures?
Yes. Seizures are a recognised complication of tramadol withdrawal, particularly with abrupt discontinuation of high doses. The seizure risk is related to tramadol’s serotonergic activity rather than its opioid activity. This risk makes medically supervised tapering, rather than abrupt cessation, the recommended approach. Anticonvulsant medications may be used during the withdrawal period to reduce seizure risk.
How long does tramadol withdrawal last?
The opioid component of tramadol withdrawal typically follows a 5 to 7 day acute course similar to other short-acting opioids. The serotonergic component (anxiety, mood disturbance, cognitive symptoms) can persist for several weeks. Post-acute withdrawal symptoms including low mood, irritability, and sleep disturbance may continue for one to three months. A medically supervised taper over two to four weeks significantly reduces the severity and duration of all withdrawal components.
Is tramadol safer than other opioids for pain management?
Tramadol has a lower overdose risk than full mu-agonist opioids when taken alone at prescribed doses. However, it is not risk-free: it carries dependence potential, seizure risk, and dangerous interactions with other serotonergic medications (SSRIs, SNRIs, MAOIs) that can cause serotonin syndrome. For short-term acute pain, it may be a reasonable option with appropriate monitoring. For chronic pain, the evidence does not support tramadol being meaningfully safer than other opioids in terms of addiction risk when used long-term.
Can I take tramadol with antidepressants?
Tramadol combined with SSRIs, SNRIs, or MAOIs increases the risk of serotonin syndrome, a potentially life-threatening condition characterised by agitation, confusion, rapid heart rate, high blood pressure, muscle rigidity, and hyperthermia. If you are taking antidepressants and prescribed tramadol, your doctor should be aware of both medications and should monitor for serotonin syndrome symptoms. In many cases, an alternative analgesic without serotonergic activity is safer.
Why is tramadol available over the counter in some countries?
Tramadol’s initial classification as unscheduled or minimally controlled in many countries reflected the belief that it had lower abuse potential than other opioids. As evidence of widespread misuse accumulated, particularly in West Africa, parts of Asia, and the Middle East, regulatory bodies began tightening controls. However, enforcement varies widely, and in many countries tramadol remains easily obtainable without a prescription, contributing to its status as one of the most misused pharmaceutical opioids globally.
Sources:
Miotto, K. et al. (2017). Tramadol: understanding the risk of this atypical opioid. Current Drug Abuse Reviews, 10(1), 3-10.
World Health Organization (2018). Tramadol: Update Review Report. WHO Expert Committee on Drug Dependence.
Grond, S. & Sablotzki, A. (2004). Clinical pharmacology of tramadol. Clinical Pharmacokinetics, 43(13), 879-923.
Tramadol, O-desmethyltramadol, M1 metabolite, CYP2D6, ultra-rapid metaboliser, mu-opioid receptor, serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, dual mechanism, seizure risk, serotonin syndrome, Schedule IV, Grunenthal, dependence, tolerance, withdrawal, buprenorphine, Suboxone, gabapentin, clonidine, WHO, Phuket Island Rehab